Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT)

CUSIP: 45258J102

Q4 2025 13F Holders as of 31 Dec 2025

Security type / class
Equity / Common Stock, par value $0.0001 per share
Total 13F shares
108,607,805
Total 13F value
$2,761,165,010
Holder snapshot 6 visible 7 signals
Share change
+13,570,331
Put/Call ratio
19%
SEC-reported price per share
$25.42
Number of holders
195
Value change
+$365,946,432
Number of buys
105
Open additional details 1 more signal available
Number of sells
78
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
202,731,676

Security key

45258J102

Report period

Q4 2025

Institutions

195

Top holders

10

IMVT full security history Ownership snapshot Full 13F holder table Newer quarter: Q1 2026 Previous quarter: Q3 2025 Immunovant, Inc. SEC filings Immunovant, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of IMVT - Immunovant, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Roivant Sciences Ltd.
Disclosed value leader
Roivant Sciences Ltd.
Comparable rows
15/15
Latest evidence
12 Dec 2025
13D/G 3/4/5 13F Lead comparable stake: 56% 13D/G row: Roivant Sciences Ltd. Showing 1-6 of 15 holder rows.

Quick read

Roivant Sciences Ltd. leads the comparable SEC ownership view at 56%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Roivant Sciences Ltd.'s linked filing trail.
Comparable ownership Top 5
Roivant Sciences Ltd. 56%
FMR LLC 8.4%
Deep Track Capital, LP 5.6%
VANGUARD GROUP INC 3.4%
ARMISTICE CAPITAL, LLC 2.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Roivant Sciences Ltd.
13D/G 3/4/5
Director, 10%+ Owner
13D/G 3/4/5
56%
$2,812,776,314
113,327,007 shares
 +$413,666,650 12 Dec 2025
FMR LLC
13D/G 13F
Company
13D/G 13F
8.4%
$237,440,423
14,729,555 shares
 -$37,858,433 30 Sep 2025
Deep Track Capital, LP
13F 13D/G
Company
13F 13D/G
5.6%
from 13D/G
$156,828,981
9,728,845 shares
 — 30 Sep 2025
VANGUARD GROUP INC
13F
Company
13F
3.4%
$110,048,178
6,826,810 shares
 — 30 Sep 2025
ARMISTICE CAPITAL, LLC
13F
Company
13F
2.9%
$94,076,320
5,836,000 shares
 — 30 Sep 2025
BlackRock, Inc.
13F
Company
13F
2.8%
$92,500,364
5,738,236 shares
 — 30 Sep 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
195
Shares
108,607,805
Rows available
195
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders
183
Q4 2025 holders
195
Holder diff
12
Investor Q3 2025 Shares Q4 2025 Shares Share Diff Share Chg % Q3 2025 value Q4 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .